SCHEMBL832366

SCHEMBL832366

CS(=O)(=O)Nc1cc(S(=O)(=O)NC(=O)c2c(-c3ccc[nH]c3=O)c3cc(Cl)ccc3n2Cc2ccnc(N)c2)ccc1O

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
PKM P14618 1/20 0.35
MCL1 Q07820 6/20 0.33
CYP2C8 P10632 1/20 0.33
PPARG P37231 3/20 0.32
MAPK8 P45983 2/20 0.32
SERPINE1 P05121 2/20 0.32
RCE1 Q9Y256 1/20 0.32
BCL2 P10415 2/20 0.31
TP53 P04637 1/20 0.31
GAA P10253 1/20 0.31
HTT P42858 1/20 0.31
HSD17B10 Q99714 1/20 0.31
F2 P00734 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL832324 0.91 SERPINE1 (0.38) KMT2APKMMCL1CYP2C8PPARG
SCHEMBL862343 0.90 MCL1 (0.37) KMT2AMCL1CYP2C8PPARGMAPK8
SCHEMBL831140 0.89 KMT2A (0.38) KMT2AMCL1CYP2C8PPARGSERPINE1
SCHEMBL831130 0.88 KMT2A (0.39) KMT2AALDH1A1MCL1CYP2C8PPARG
SCHEMBL832479 0.88 KMT2A (0.38) KMT2AMCL1CYP2C8PPARGSERPINE1
SCHEMBL832230 0.88 KMT2A (0.39) KMT2AMEN1MCL1CYP2C8PPARG
SCHEMBL831545 0.88 KMT2A (0.40) KMT2AMEN1ALDH1A1MCL1CYP2C8
SCHEMBL832303 0.88 PPARG (0.37) KMT2AMEN1MCL1CYP2C8PPARG
SCHEMBL832375 0.87 KMT2A (0.42) KMT2AMCL1CYP2C8PPARGSERPINE1
SCHEMBL831696 0.87 PPARG (0.38) KMT2AMEN1MCL1CYP2C8PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 KMT2A 321/4885MEN1 2084/4885ALDH1A1 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.